BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Torres-Ferrús M, Ursitti F, Alpuente A, Brunello F, Chiappino D, de Vries T, Di Marco S, Ferlisi S, Guerritore L, Gonzalez-Garcia N, Gonzalez-Martinez A, Khutorov D, Kritsilis M, Kyrou A, Makeeva T, Minguez-Olaondo A, Pilati L, Serrien A, Tsurkalenko O, Van den Abbeele D, van Hoogstraten WS, Lampl C; School of Advanced Studies of European Headache Federation (EHF-SAS). From transformation to chronification of migraine: pathophysiological and clinical aspects. J Headache Pain 2020;21:42. [PMID: 32349653 DOI: 10.1186/s10194-020-01111-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 26] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Pistoia F, Salfi F, Saporito G, Ornello R, Frattale I, D'Aurizio G, Tempesta D, Ferrara M, Sacco S. Behavioral and psychological factors in individuals with migraine without psychiatric comorbidities. J Headache Pain 2022;23:110. [PMID: 36028795 DOI: 10.1186/s10194-022-01485-x] [Reference Citation Analysis]
2 Zhang W, Lei M, Wen Q, Zhang D, Qin G, Zhou J, Chen L. Dopamine receptor D2 regulates GLUA1-containing AMPA receptor trafficking and central sensitization through the PI3K signaling pathway in a male rat model of chronic migraine. J Headache Pain 2022;23:98. [PMID: 35948867 DOI: 10.1186/s10194-022-01469-x] [Reference Citation Analysis]
3 Reducha PV, Edvinsson L, Haanes KA. Could Experimental Inflammation Provide Better Understanding of Migraines? Cells 2022;11:2444. [DOI: 10.3390/cells11152444] [Reference Citation Analysis]
4 Argyriou AA, Dermitzakis EV, Vlachos GS, Vikelis M. Long-term adherence, safety, and efficacy of repeated onabotulinumtoxinA over five years in chronic migraine prophylaxis. Acta Neurol Scand 2022;145:676-83. [PMID: 35170031 DOI: 10.1111/ane.13600] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Davis L, Torphy B. Managing migraine on the frontline: Identifying disease, understanding burden, and incorporating CGRP pathway-targeting therapies in primary care. British Journal of Pain. [DOI: 10.1177/20494637221104292] [Reference Citation Analysis]
6 De Matteis E, Sacco S, Ornello R. Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes. TCRM 2022;Volume 18:359-78. [DOI: 10.2147/tcrm.s263825] [Reference Citation Analysis]
7 Mungoven TJ, Henderson LA, Meylakh N. Chronic Migraine Pathophysiology and Treatment: A Review of Current Perspectives. Front Pain Res (Lausanne) 2021;2:705276. [PMID: 35295486 DOI: 10.3389/fpain.2021.705276] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Law EF, Connelly M. Introduction to Special Section: Innovations in Pediatric Headache Research. Journal of Pediatric Psychology 2022. [DOI: 10.1093/jpepsy/jsac023] [Reference Citation Analysis]
9 Hirata K, Takeshima T, Sakai F, Imai N, Matsumori Y, Tatsuoka Y, Numachi Y, Yoshida R, Peng C, Mikol DD, Lima GPDS, Cheng S. Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double-blind, placebo-controlled studies. Brain Behav 2022;:e2526. [PMID: 35201674 DOI: 10.1002/brb3.2526] [Reference Citation Analysis]
10 Amiri P, Kazeminasab S, Nejadghaderi SA, Mohammadinasab R, Pourfathi H, Araj-khodaei M, Sullman MJM, Kolahi A, Safiri S. Migraine: A Review on Its History, Global Epidemiology, Risk Factors, and Comorbidities. Front Neurol 2022;12:800605. [DOI: 10.3389/fneur.2021.800605] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Pan Q, Wang Y, Tian R, Wen Q, Qin G, Zhang D, Chen L, Zhang Y, Zhou J. Sphingosine-1 phosphate receptor 1 contributes to central sensitization in recurrent nitroglycerin-induced chronic migraine model. J Headache Pain 2022;23:25. [PMID: 35144528 DOI: 10.1186/s10194-022-01397-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Mechtler L, Saikali N, McVige J, Hughes O, Traut A, Adams AM. Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine. Front Neurol 2021;12:788159. [PMID: 35069416 DOI: 10.3389/fneur.2021.788159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Mozafarihashjin M, Togha M, Ghorbani Z, Farbod A, Rafiee P, Martami F. Assessment of peripheral biomarkers potentially involved in episodic and chronic migraine: a case-control study with a focus on NGF, BDNF, VEGF, and PGE2. J Headache Pain 2022;23:3. [PMID: 34991456 DOI: 10.1186/s10194-021-01377-6] [Reference Citation Analysis]
14 Nierenburg H, Stark-Inbar A. Nerivio® remote electrical neuromodulation for acute treatment of chronic migraine. Pain Manag 2021. [PMID: 34538078 DOI: 10.2217/pmt-2021-0038] [Reference Citation Analysis]
15 Silvestro M, Tessitore A, Scotto di Clemente F, Battista G, Tedeschi G, Russo A. Refractory migraine profile in CGRP-monoclonal antibodies scenario. Acta Neurol Scand 2021;144:325-33. [PMID: 34019304 DOI: 10.1111/ane.13472] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
16 Argyriou AA, Mitsikostas DD, Mantovani E, Vikelis M, Tamburin S. Beyond chronic migraine: a systematic review and expert opinion on the off-label use of botulinum neurotoxin type-A in other primary headache disorders. Expert Rev Neurother 2021;:1-22. [PMID: 34289791 DOI: 10.1080/14737175.2021.1958677] [Reference Citation Analysis]
17 Vo P, Swallow E, Wu E, Zichlin ML, Katcher N, Maier-Peuschel M, Naclerio M, Ritrovato D, Tiwari S, Joshi P, Ferraris M. Real-world migraine-related healthcare resource utilization and costs associated with improved vs. worsened/stable migraine: a panel-based chart review in France, Germany, Italy, and Spain. J Med Econ 2021;24:900-7. [PMID: 34311659 DOI: 10.1080/13696998.2021.1953301] [Reference Citation Analysis]
18 Torres-Ferrus M, Pareto D, Gallardo VJ, Cuberas-Borrós G, Alpuente A, Caronna E, Vila-Balló A, Lorenzo-Bosquet C, Castell-Conesa J, Rovira A, Pozo-Rosich P. Cortical metabolic and structural differences in patients with chronic migraine. An exploratory 18FDG-PET and MRI study. J Headache Pain 2021;22:75. [PMID: 34273945 DOI: 10.1186/s10194-021-01289-5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
19 Caponnetto V, Deodato M, Robotti M, Koutsokera M, Pozzilli V, Galati C, Nocera G, De Matteis E, De Vanna G, Fellini E, Halili G, Martinelli D, Nalli G, Serratore S, Tramacere I, Martelletti P, Raggi A; European Headache Federation School of Advanced Studies (EHF-SAS). Comorbidities of primary headache disorders: a literature review with meta-analysis. J Headache Pain 2021;22:71. [PMID: 34261435 DOI: 10.1186/s10194-021-01281-z] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
20 Winner PK, McAllister P, Chakhava G, Ailani J, Ettrup A, Krog Josiassen M, Lindsten A, Mehta L, Cady R. Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial. JAMA 2021;325:2348-56. [PMID: 34128999 DOI: 10.1001/jama.2021.7665] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 18.0] [Reference Citation Analysis]
21 Spuntarelli V, Negro A, Luciani M, Bentivegna E, Martelletti P. Eptinezumab for the treatment of migraine. Expert Opin Biol Ther 2021;21:999-1011. [PMID: 34009094 DOI: 10.1080/14712598.2021.1931678] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Mathur V, Komala S, Jhamb D, Prakash J, Somasekharan M. Is psychiatric morbidity in chronic migraine associated with poor outcome: Experience from a tertiary care centrer. Ind Psychiatry J 2020;29:317-22. [PMID: 34158719 DOI: 10.4103/ipj.ipj_187_20] [Reference Citation Analysis]
23 Wang X, Yin Z, Lian Y, Xu Y, Li Y, Liu J, Gu Q, Yan F, Ge Z, Lian Y, Hu D, Chen S, Wang R, Chen X, Liu J, Zhang M, Ran Y, Zhou P, Ma J, Lv X, Dong Z, Yu S. Premonitory symptoms in migraine from China: A multi-clinic study of 4821 patients. Cephalalgia 2021;41:991-1003. [PMID: 33631964 DOI: 10.1177/0333102421997850] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Ashina S, Bentivegna E, Martelletti P, Eikermann-Haerter K. Structural and Functional Brain Changes in Migraine. Pain Ther 2021;10:211-23. [PMID: 33594593 DOI: 10.1007/s40122-021-00240-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Connelly MA, Boorigie ME. Feasibility of using "SMARTER" methodology for monitoring precipitating conditions of pediatric migraine episodes. Headache 2021;61:500-10. [PMID: 33382086 DOI: 10.1111/head.14028] [Reference Citation Analysis]
26 Cornelison LE, Hawkins JL, Woodman SE, Durham PL. Noninvasive vagus nerve stimulation and morphine transiently inhibit trigeminal pain signaling in a chronic headache model. Pain Rep 2020;5:e881. [PMID: 33364541 DOI: 10.1097/PR9.0000000000000881] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]